



## Company Overview

Fortress Biotech, Inc. ("Fortress") is an innovative biopharmaceutical company focused on acquiring and advancing assets to enhance long-term value for shareholders through product revenue, equity holdings and dividend and royalty income. The company has a portfolio of multiple marketed prescription pharmaceutical products and programs in development at Fortress, at its majority-owned and majority-controlled partners and subsidiaries and at partners and subsidiaries it founded and in which it holds significant minority ownership positions. Fortress' portfolio is being commercialized and developed for various therapeutic areas including oncology, dermatology, and rare diseases. Fortress' model is focused on leveraging its significant biopharmaceutical industry expertise and network to further expand and advance the company's portfolio of product opportunities. Fortress has established partnerships with some of the world's leading academic research institutions and biopharmaceutical companies to maximize each opportunity to its full potential, including AstraZeneca, City of Hope, Nationwide Children's Hospital, Columbia University, Dana Farber Cancer Center and Sentyln Therapeutics.

## Journey Medical Corporation to Announce Second Quarter 2026 Financial Results on August 12, 2026

Aug 5 2026, 8:30 AM EDT

## Fortress Biotech and Subsidiary Urica Therapeutics Announce Crystalys Therapeutics' \$130 Million Series B Financing

Jul 27 2026, 8:00 AM EDT

## Journey Medical Corporation to Participate in A.G.P.'s Annual Virtual Healthcare Conference

May 19 2026, 4:45 PM EDT

## Stock Overview

|               |                 |
|---------------|-----------------|
| Symbol        | FBIO            |
| Exchange      | Nasdaq          |
| Market Cap    | 86.7m           |
| Last Price    | \$2.61          |
| 52-Week Range | \$1.83 - \$4.53 |

08/11/2026 08:00 PM EDT

## Investor Relations

Jaclyn Jaffe  
Nicole McCloskey  
T: 781-652-4500  
[ir@fortressbiotech.com](mailto:ir@fortressbiotech.com)

## Management Team

### Lindsay A. Rosenwald, M.D.

Chairman, President and Chief Executive Officer

### Michael S. Weiss

Executive Vice Chairman, Strategic Development

### David Jin

Chief Financial Officer and Head of Corporate Development

## Fortress Biotech, Inc.

1111 Kane Concourse  
Suite 301  
Bay Harbor Islands, FL 33154

## Disclaimer

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and

uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.